Aim The aim was to develop and validate a simple scoring system evaluating the impact of colostomy dysfunction on quality of life (QOL) in patients with a permanent stoma after rectal cancer treatment.
Introduction
Stoma formation may be necessary after bowel surgery and involves diversion of the bowel to the skin, where the gut contents are emptied into a bag. Data from Denmark and the UK indicate that, in northern Europe, 2000 people per million are at present living with a stoma [1, 2] .
Stomas are formed for a range of indications, including colorectal cancer, inflammatory bowel disease and other benign conditions. The majority of ileostomies are temporary diverting loop stomas, which are typically subsequently reversed. However, a proportion of ileostomies and most colostomies are end stomas, which are usually permanent.
In the treatment of rectal cancer, low anterior resection (LAR) with sphincter-preserving surgery following the principles of total mesorectal excision is the current gold standard treatment. In cases where the tumour threatens the sphincteric apparatus, an abdomino-perineal excision (APE) is performed. Hartmann's procedure is chosen in a selected group of patients in whom an attempted primary anastomosis is not safe or technically feasible. An APE and many Hartmann's procedures will result in a permanent end colostomy [3] [4] [5] .
Previous studies have investigated the impact of living with a stoma on health-related quality of life (QOL) and have reported wide-ranging and contradictory conclusions [6] [7] [8] [9] . A Cochrane review from 2012 investigated QOL, with or without a permanent stoma, after rectal cancer resection, comparing sphincter-preserving surgery to APE/Hartmann's procedure. It concluded that because of clinical heterogeneity and different study designs, a meta-analysis was not possible. However, it was suggested that patients living with a permanent colostomy after APE or Hartmann's procedure did not appear to have a poorer QOL compared to those undergoing LAR without a permanent stoma [10] . Whilst the overall effects on QOL may be unclear, stomas are expected to be associated with several potential morbidities such as parastomal skin problems and herniation. Additionally, living with a stoma can give rise to multiple patient concerns, such as altered body image, sexual and relationship issues, and can impact on activities of daily living [11, 12] .
The aim of this study was to develop and validate a simple scoring system for evaluating stoma impact in patients with a permanent colostomy after rectal cancer resection. Development was based on directly patientreported outcome measures concerned with various aspects of daily life with a stoma, mapped against overall QOL scores.
Method Population
In this population-based study, eligible patients for inclusion were identified by the Danish Colorectal Cancer Group's national registry. This national multidisciplinary cancer group maintains a prospectively collected database of all colorectal cancer patients and treatment across Denmark [13] . Data on rectal cancer patients with a permanent end colostomy from either APE or Hartmann's procedure from May 2001 to April 2007 were extracted. By crosschecking data with the National Patient Registry and the Civil Registration System, patients with previous or synchronous cancer (except spinocellular and basocellular carcinoma of the skin) and those with dementia or who had died were excluded. The patients' general practitioners were contacted to obtain additional information regarding mental state and linguistic abilities; those who were known to be unable to understand the Danish language were also not included.
Questionnaires
The basic stoma questionnaire (BSQ) was previously developed in our department [14] . It consists of 22 questions with a variable number of response options regarding different aspects of life with a stoma. It also includes one anchor question addressing the overall impact of the stoma on QOL as follows: 'Overall, how much do you think that the stoma influences your quality of life?' The response options are 'no', 'minor', 'some' or 'major'.
In brief, the development of the BSQ was based on a literature review, discussion and revision by a panel of experts, and pilot testing. The literature review initially generated a primary list of possible items/questions. This list was then evaluated by a group of seven experts, who comprised four colorectal surgeons, a gastroenterologist, an oncologist and an epidemiologist. All members of the group have a special interest in stoma function. Each item was thoroughly discussed. The questionnaire was piloted in a randomly selected group of eligible patients; they were asked to read the questions with focus on importance, relevance and wording and to suggest any additional relevant components. After editing, a second round of testing was performed on 15 new patients resulting in no need for further changes. For the purposes of presenting this paper, the final score, the scoring manual, and the basic stoma questionnaire were professionally backward and forward translated from Danish into English according to WHO guidelines [15] (Appendices S1-S3). Of the original 22 items, five items were excluded from the analyses, three items due to close similarity to the anchor question and two items regarding general abdominal pain were not considered relevant to the colostomy impact (CI) score (Appendix S3).
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) C30 is a 30-item self-administered questionnaire. It measures multiple dimensions of health-related QOL in cancer patients. The questionnaire has five functional subscales and nine symptom subscales. Scoring of the data was performed using the EORTC scoring manual [16, 17] . All of the EORTC scores were linearly transformed to a scale of 0-100 points. A mean difference of AE5-10 points represented a small but relevant clinical difference, whereas a difference of AE10-20 points represented a moderate clinically relevant difference. A high functional score represented a high level of function, with an optimal score of 100. A high symptom score represented a high level of symptoms, with an optimal score of 0 [18] .
Development and validation of the colostomy impact score
The large number of patients included enabled both development and internal validation of the colostomy impact (CI) score. It was developed based on the results of 17 relevant items in the BSQ from a randomly selected half of the study population, adjusted for age, gender and chemoradiotherapy, and subsequently validated in the remaining half. Since logistic regression analysis is applicable only to a binary outcome, the anchor question response options were reduced into two QOL groups of 'no/minor' and 'some/major' impact on QOL. Each item was then correlated to QOL by odds ratio. Only items with a statistically significant contribution were included in the final model. A multivariate analysis was performed to compute the adjusted odds ratio for each of the remaining items. To create an additive model and so that individual items contribute to the total score, the logarithmic values of the adjusted odds ratios were calculated, multiplied by an appropriate factor and rounded to obtain an integer score value. The individual maximum scores for all symptoms were combined to give the maximum CI score possible.
The score was then plotted against the two QOL groups ('no/minor' and 'some/major') and the score was divided into groups of minor colostomy impact (Minor CI) and major colostomy impact (Major CI). Based on receiver operating characteristic (ROC) curve analysis and sensitivity analyses, a cut-off value to distinguish between Minor CI and Major CI was chosen. The validity was investigated comparing the score in the development cohort and the validation cohort. ROC curve analysis computed the sensitivity and specificity for the chosen cut-off value. The EORTC QLQ scales were utilized to find out whether patients in the Major CI group had substantial lower QOL than patients in the Minor CI group. EORTC QLQ data are presented as mean values, despite the skewed distribution, owing to the convention of EORTC data handling [16] . However, differences between the two groups were calculated with the non-parametric Wilcoxon rank sum test.
Results

Overall cohort characteristics
Of the 6398 rectal cancer patients treated from 2001 to 2007, patients were excluded due to previous cancer (n = 2764), disseminated or non-radical resection (n = 910) and death/research protection (n = 574). A few patients were excluded due to recurrence of disease (n = 55) and linguistic/mental challenge/dementia (n = 235). This left 1860 eligible patients, of whom 1187 had primary anastomosis (with or without temporary diverting stoma). There were 63 non-responders leaving a total cohort of 610 patients for this study. Of these 448 (73.4%) had undergone APE and 162 (26.6%) had undergone Hartmann's procedure (Fig. 1) . The median follow-up time between surgery and survey was 4.6 years (IQR 3.2-6.2). We found no statistically significant differences in demographics between the development and the validation cohorts (Table 1) .
Development phase
Of the 17 relevant items, items 7 and 8 regarding stool consistency were interlinked posing almost the same question. Therefore both items could not be included in the score and item 7 was excluded since it demonstrated the least diagnostic fidelity of the two. Nine items were excluded due to a non-significant impact on QOL, leaving seven items that were significantly associated with impaired QOL (Fig. 2) . Multivariate analyses computed the adjusted odds ratio for each of the seven items. The coefficients were logarithmically transformed and, for simplicity purposes only, multiplied by 5 labelling the items with a more convenient score value (Table 2) . Applying the CI score to the entire cohort we found a substantial increasing median CI score through the four different QOL groups (Fig. 3) . The majority of patients were concentrated in the no and minor impact group, which encompassed 81% of the population, while major impact was reported by only 5%. Owing to the small number of patients in the some and major group we found it more convenient to make two QOL groups corresponding to Minor CI and Major CI. The total score value ranged from 0 to 38 points. The highest possible sensitivity and specificity cut-off value was chosen as 10. Scores of 0-9 were equivalent to Minor CI, while scores ≥ 10 were equivalent to Major CI.
Before deciding on the final cut-off level of 10, sensitivity analyses of other cut-off values were done. Choosing 8 as the cut-off the sensitivity/specificity would have been 85.7%/47.8%, and likewise, if choosing a level of 12, the sensitivity/specificity would have been 77.6%/65.8%.
Validation phase
The ROC curve shows the relation between CI score and some/major impact on QOL in the validation cohort (area under the curve 0.7964), with a sensitivity of 85.7% and a specificity of 59.5% (Fig. 4) . Differences in the CI score between the two QOL groups were statistically significant. For patients reporting no/minor impact on QOL, the median CI score was 8 (IQR 4-13) and for those reporting some/major impact on QOL the median CI score was 18 (IQR 13-21) (Fig. 5) . A two by two contingency table shows the distribution of patients in the CI score groups (Table 3 ). 
No impact
Comparison with EORTC QLQ
We found statistically significant differences in EORTC QLQ for all functional and symptom scales comparing the Minor CI group and the Major CI group (Fig. 6) . The largest differences in the EORTC mean score were found in global health status (mean score difference of 13), role functioning (mean score difference of 14), social functioning (mean score difference of 12) and on the symptom scale fatigue (mean score difference of 14).
Discussion
In this study, we have developed and validated the first scoring system for reliable quantification of the negative impact on QOL for patients living with an end colostomy. The final score includes the seven factors that most strongly and consistently impact an individual's QOL. We used a proven methodology to develop the score, with extensive involvement of both experts and stoma patients at multiple points.
The seven items included in the final score were as follows: odour, leakage, stool consistency, pain at the stoma site, skin problems, herniation and stoma management help. From a clinical point of view, we postulated that odour, leakage and skin problems would probably have a high impact on QOL and therefore predicted these would be important in the final scoring tool. However, the items with the highest scores proved to be herniation, stool consistency and stoma management help, which was unexpected.
Parastomal hernia is a frequent complication of end colostomy. The rate varies in the literature depending on the length of follow-up and method of detection, but most accept rates of 30%-60% [19] [20] [21] . In our There was a significant difference in the CI score between the two groups (P < 0.001). Table 3 Distribution of patients between groups in the validation cohort.
CI score group
No/minor impact on QOL Some/major impact on QOL Total   Minor CI 132  7  139  Major CI  90  42  132  Total  222  49  271 development cohort, 59% of patients reported herniation. There is no gold standard detection method for diagnosis of parastomal hernia. The most frequently used method is CT scan (with/without Valsalva manoeuvre), which has shown a better detection rate than clinical examination [22, 23] . In our study the detection method for parastomal hernia was purely by self-reporting, since our aim was to develop a scoring tool based on the patient's perspective. Parastomal bulging can be caused by fatty mesentery or excessive subcutaneous length of the stoma. Therefore, a bulge does not necessarily represent a hernia. Consequently an overestimation of the prevalence of parastomal hernia is probable. Further, using self-assessment an underestimation of the true prevalence of parastomal hernia is also a possibility, since some hernias are symptom-free and only diagnosed with imaging assistance. However, for the purpose of constructing this score, small and symptom-free parastomal bulges will be less significant. Of course, it would be interesting to investigate selfreported bulging/hernia vs clinical examination vs imaging techniques but this was outside the remit of the current study. Whilst only a minor proportion of the development cohort experienced altered stool consistency to separate hard lumps, this resulted in a score value of 8, demonstrating a major impact on QOL. Watery and variable stool was reported by 34%, each with a high score value of 6. Notably, we found that 10% of the patients needed help taking care of their stoma. It follows that patients requiring help with the day-to-day management of their stoma would experience a significant impact on their QOL, which is corroborated by the high score value of 8.
Across the entire cohort we observed a clear linearity in median CI score, increasing from no impact on QOL to major impact on QOL. The distribution of patients in the four QOL categories was uneven; therefore we decided to reduce the four QOL groups into two groups as no/minor impact on QOL and some/major impact on QOL, attaining the two score groups of Minor CI and Major CI which made the score simpler and easier to use. It is important to note that not all stoma patients experienced an impact on QOL. Nevertheless, patients reporting no impact on QOL had a median CI score of 6 (IQR 2-8).
Internal validation showed corresponding score results in the development and the validation cohort. To distinguish between the two score groups, a cut-off value of 10 was obtained, prioritizing high sensitivity over high specificity. Low specificity is acceptable because the false positive group can choose to reject further counselling. It would be less desirable to neglect the false negative group (Table 3) . Major CI was associated with an impact on all aspects of QOL. Unsurprisingly, the most important domains with clinical relevance and a difference in mean score of 10-20 points were global health status, role functioning, social functioning and fatigue. These are all aspects of QOL one would expect to be influenced by stoma problems.
A primary strength of the study was the well-defined and large cohort. We utilized a predefined strict methodology for each stage of the study. Our group has had proven success with this system, having previously developed the low anterior resection syndrome score (LARS score) [24] , which has been widely used by researchers internationally and is now validated in all main languages [25, 26] . The study population available for use was large, which enabled internal validation, where we found a high correlation between the development and the validation cohort with a high sensitivity. Lastly, a high CI score was reflected in all general aspects of QOL regarding the EORTC QLQ C30 scales.
The study also has some limitations. Our study design meant that we excluded some large groups of patients, for example those with previous cancer, who could have been eligible to contribute. However, we wanted to reduce hypothetical bias consequent to radiotherapy or/and chemotherapy for other malignant diseases. Our cohort consists of Danish patients only. There is no doubt that there are significant social, cultural and demographic differences regarding living with and acceptance of a stoma. Similarly, QOL may be perceived differently across various populations [27, 28] . The economic impacts of having a stoma may differ across countries, and it should be noted that, in Denmark, stoma appliances are provided free of charge to patients. Also, in Denmark all patients are offered preoperative and postoperative counselling by a stoma therapy specialist. Hence, external validation is therefore crucial and already a work in progress. The CI score has been developed only for colostomy patients. Ileostomy patients could have other issues that might differently impact QOL and, as such, this score may not be directly applicable to ileostomy patients.
In the outpatient setting, the primary focus is often on oncological outcomes. Therefore, it can be difficult and time consuming to address all problems that follow treatment for rectal cancer. Tools such as the CI score and the LARS score make it possible to screen patients for functional outcome deficits in a couple of minutes. These tools can also be self-administered by patients at appropriate postoperative time points, either at home or in the clinic waiting room. We propose that the CI score will have a place in further international research of functional outcome after rectal cancer treatment. It allows investigation of stoma function and impact on QOL in a standardized and validated way.
In the future, we shall test and validate the score in other cultures and languages. If the CI score demonstrates general validity, we shall have developed a new patient-based scoring system for rectal cancer surgery. With the LARS score and the CI score, we shall then have tools that cover all bowel dysfunction after rectal cancer resection, with the LARS score for sphincter-preserving surgery and the CI score for patients with permanent colostomy.
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